metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)
versus placebo
	nivolumab alone vs. placebo	1	-	-	-
mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	camrelizumab alone vs. Standard of Care (SoC)	1	-1138 [-1854; -422] /10000 172/228 vs. 191/220	951 [273; 1628] /10000 202/228 vs. 174/220	-
	nivolumab alone vs. Standard of Care (SoC)	1	-658 [-1429; 112] /10000 160/210 vs. 173/209	484 [-167; 1134] /10000 187/210 vs. 176/209	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-	-